Johnson & Johnson CEO Alex Gorsky Photograph by Stuart Isett/Fortune

Johnson & Johnson, the world’s number one producer of healthcare products is pursuing an acquisition surgical robotics firm Auris Health, Bloomberg reports, looking to acquire the firm at a premium to its valuation pegged at about $2 billion according to a source. Such an acquisition would mark one of the largest for the New Jersey based healthcare giant, but quite less than its $30 billion acquisition of Actellion Pharmceuticals in January 2017.

Auris Health founded in 2007 has raised some $730 million in funding according to Crunchbase data. Investors include Lux Capital, Wellington Management, D1 Capital Partners, Viking Global and  Peter Thiel’s Mithrial Capital Management. The company produces robotic surgical scopes operated by a device similar to a video game controller which are steered into a patient’s lungs where they can be used to identify cancerous tumors.

No final agreements have been reached yet with no certainty of a deal set, Bloomberg says.

Share this...

Facebook

Pinterest

Twitter

Linkedin

Whatsapp

Email

Print